WallStSmart

Merit Medical Systems Inc (MMSI)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 3568% more annual revenue ($56.58B vs $1.54B). NVS leads profitability with a 23.9% profit margin vs 9.0%. MMSI appears more attractively valued with a PEG of 1.29. MMSI earns a higher WallStSmart Score of 61/100 (C+).

MMSI

Buy

61

out of 100

Grade: C+

Growth: 7.3Profit: 6.0Value: 5.3Quality: 7.5
Piotroski: 5/9Altman Z: 2.43

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MMSIOvervalued (-14.4%)

Margin of Safety

-14.4%

Fair Value

$71.03

Current Price

$61.63

$9.40 premium

UndervaluedFair: $71.03Overvalued
NVSSignificantly Overvalued (-52.0%)

Margin of Safety

-52.0%

Fair Value

$109.95

Current Price

$148.34

$38.39 premium

UndervaluedFair: $109.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MMSI2 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
38.8%8/10

Earnings expanding 38.8% YoY

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$275.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

MMSI1 concerns · Avg: 4.0/10
P/E RatioValuation
26.7x4/10

Moderate valuation

NVS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.562/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : MMSI

The strongest argument for MMSI centers on Price/Book, EPS Growth. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : MMSI

The primary concerns for MMSI are P/E Ratio.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

MMSI profiles as a value stock while NVS is a declining play — different risk/reward profiles.

MMSI carries more volatility with a beta of 0.65 — expect wider price swings.

MMSI is growing revenue faster at 7.5% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MMSI scores higher overall (61/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merit Medical Systems Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, intensive care, and endoscopy. The company is headquartered in South Jordan, Utah.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?